null

null

null

null

null

null

null

null

null

Minimal debt; cash-funded clinical-stage biotech with ~$200M+ cash runway, near-zero leverage ratio

Negligible debt service impact; rising rates marginally reduce investment income on cash reserves, immaterial to operations

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Single-source API manufacturers in EU/India for luspatercept-class peptides; 2) Chinese raw material suppliers for peptide synthesis

No international revenue yet; pre-commercial stage, so sovereign currency devaluation exposure is effectively zero currently

Primarily US-based clinical operations; no commercial international revenue markets, so currency devaluation risk is negligible

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single CDMO/CRO partners for drug substance manufacturing; likely one supplier exceeds 30% of operational input cost

Clinical-stage biopharmaceutical R&D; revenue model is milestone/grant-based, not SaaS; cloud disruption would delay trials, not halt revenue

Secondary: potential future royalty/licensing model post-approval; cloud termination would disrupt data management but not core IP

Moderate API coupling risk to clinical data platforms (Medidata, Veeva); switching mid-trial would be costly and FDA-complicating

Low Howey risk; equity-funded biotech with no token issuance; common shares are conventional securities, not investment contracts

Very High

Moderate GDPR exposure via EU clinical trial patient data; CCPA exposure limited; compliance costs manageable but non-trivial

Low antitrust risk; niche rare hematology/musculoskeletal market with no dominant market share; no bundling or exclusivity concerns

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Pre-commercial; ~100% transactional/milestone-based from partnerships; zero recurring subscription revenue currently

Future monetization via drug sales royalties, licensing milestones, and potential co-commercialization agreements with large pharma partners

No commercial pricing yet; future orphan drug pricing likely $100K–$300K/year per patient, justified by rare disease premium and clinical benefit

High potential pricing power in rare hematologic diseases; orphan drug designation and limited competition support premium pricing

Target gross margin 70–85% at commercial scale, typical for specialty/orphan biopharmaceuticals with CDMO manufacturing

No free-rider problem; prescription biologic with no generic substitute risk until patent expiry; patient persistence typically high

Revenue growth sublinear to headcount post-commercialization; R&D phase is headcount-intensive but commercial scale leverages existing infrastructure

Marginal cost of growth low post-approval; incremental revenue from new prescriptions requires minimal additional headcount or capex

Not applicable; Keros is not a franchise business model

At 10x scale, CAC remains low via targeted rare disease KOL networks; patient identification costs rise but unit economics remain favorable

No meaningful network effects; drug efficacy and physician adoption drive uptake, not user-base size

27.2% Return on Assets (Strong)

High recession resistance; rare disease therapies with no alternatives are medically necessary, insulated from discretionary spending cuts

Patients with rare hematologic disorders (MDS, beta-thalassemia, myelofibrosis); concentrated rare disease population

Hematology/oncology specialists and academic medical centers prescribing for rare anemia and musculoskeletal conditions

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.6% CapEx / Revenue (Low-CapEx Asset-Light)

0001664710

KROS